{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"groups":[{"description":"166 subjects received oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).\n\nOral Testosterone Undecanoate: Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \\< 350 ng/dL, decreased if \\> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.","id":"OG000","title":"Oral Testosterone Undecanoate"},{"description":"56 subjects were randomly assigned to the Axiron treatment group and began treatment at a dose of 60 mg every morning.\n\nAxiron Testosterone Topical Solution: Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.\n\nSerial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \\< 350 ng/dL, decreased if \\> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.","id":"OG001","title":"Axiron Testosterone Topical Solution"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-treat study population All subjects randomized to either Oral TU or Axiron","reportingStatus":"POSTED","timeFrame":"Day 105","title":"Number of Oral TU Treated Subjects Who Have a Total T Cavg in the Eugonadal Range of 252 to 907 ng/dL at Visit 7","type":"PRIMARY","unitOfMeasure":"Participants"}